Available online on 15.07.2021 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2021 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access  Full Text Article                                                                                                                                        Review Article

A Review on Central Pontine Myelinolysis and Correction of Hyponatremia in Hospitalized Patients

*Anju Joy , Bincy T. Abraham, K. Krishnakumar

Department of Pharmacy Practice, St. James college of Pharmaceutical Sciences, St. James’ Hospital Trust Pharmaceutical Research Centre (DSIR Recognized), Chalakudy-680307, Kerala, India

Article Info:

___________________________________________

Article History:

Received 14 May 2021     

Review Completed 23 June 2021

Accepted 30 June 2021 

Available online 15 July 2021 

___________________________________________

Cite this article as:

Joy A, Abraham BT, Krishnakumar K, A Review on Central Pontine Myelinolysis and Correction of Hyponatremia in Hospitalized Patients, Journal of Drug Delivery and Therapeutics. 2021; 11(4):138-140

DOI: http://dx.doi.org/10.22270/jddt.v11i4.4876                    

 

Abstract

______________________________________________________________________________________________________

Pontine myelinolysis (PM) can be a nerve disorder represented by pons demyelination. it is characterized by damage to regions of the brain, most commonly tracts pontine substantia alba, after rapid correction of metabolic disorders such as hyponatremia. PM (Pontine Myelinolysis) is categorized into Central pontine myelinolysis (CPM) and extra pontine myelinolysis (EPM). The various studies revealed that quick correction of hyponatremia plays a vital role in the pathogenesis of ODS. Prevention of ODS must be conducted by gradually increasing sodium concentration of 4–6 mmol/Lin in any 24-h period. PubMed and Medline literature search was done using CPM and hyponatremia as keywords. The principal aim of this review is to encapsulate, the recent evidence from literature about the association between rapid correction of hyponatremia and central pontine myelinolysis.

Keywords: Demyelination syndrome, EPM, CPM, Serum tonicity, Hyponatremia, Demyelination

*Address for Correspondence: 

Anju Joy, Department of Pharmacy Practice, St. James college of Pharmaceutical Sciences, St. James’ Hospital Trust Pharmaceutical Research Centre (DSIR Recognized), Chalakudy-680307, Kerala, India. ORCID ID: https://orcid.org/0000-0002-1349-1449

 


INTRODUCTION

Central pontine myelinolysis could also be a neurological disorder that the majority of frequently occurs after too rapid medical correction of sodium deficiency (hyponatremia). It was first described in 1959 by Adams and his colleagues during a report of 4 patients with pseudobulbar palsy and quadriplegia. The starting cases were seen in patients with alcohol use disorder and malnutrition; nevertheless, by the 1970s, successive cases showed a link with rapid sodium correction.1

The rapid rise in serum sodium (osmolarity), results in water moving out of the cell leading to their dryness and destruction of myelin. Pons is the main part of the brain which is exposed by myelinolysis.  Myelinolysis may affect the other areas of the brain, which is called extra pontine myelinolysis. 2

Clinical features of CPM usually begin to appear several days after the rapid correction of low sodium. Symptoms may vary and can range from encephalopathy to coma and death.

EPIDEMIOLOGY

The incidence of CPM is not well known due to underdiagnosis. A 2015 retrospective study shows that the prevalence of ODS is 2.5% between ICU admissions.

SIGNS AND SYPMTOMS

 

 

COMMON CLINICAL SYMPTOMS BY SITE OF MANIFESTATION AND SYNDROME CLASSIFICATION

CPM

                                                    EPM

Pontine symptoms

Movement disorders

Neurobehavioral problems

Coma

Bradykinesia,rigidty

Encephalopathy

Locked- in syndrome

Tremor

Epileptic seizures

Paresis

Dystonia

Mutism

Dysarthria

Chorea,choreoathetosis

Catatonia

Dysphagia

Myoclonus

Apathy, lethargy

Pupillary and Ocular motility disorders

Gait disorder

Depression

Loss of reflexes

Ataxia

Emotional instability,dementia

 

 


ETIOLOGY

PATHOPHYSIOLOGY

 

Figure 1: Restoration of cellular space in the settings of hyponatremia 7

Figure 2: Demyelination and apoptosis of cells with quick correction of hyponatremia 8

DIAGNOSIS

The suspicion is established by the demonstration by magnetic resonance of the demyelination sites, typically positioned in the pons, cerebellum, lateral geniculate body, thalamus and external and terminal capsules. Brain stem damage can be detected by electrophysiological diagnoses as supporting evidence.

TREATMENT

The primary treatment of CPM is to adjust sodium.it should not be more than 8 to 12 m Eq / L for 24 hours. if the patients had acute hyponatremia, the rate of adjusting the sodium should not more than 6to8 m Eq / L for 24 hours. 9

In case of chronic or severe hyponatremia (serum sodium less than120 m Eq / L) with neurological symptoms, a 3% hypertonic saline solution should be given.

If the patient had no other neurological symptoms, the main aim of the treatment is slow sodium correction rate with iv fluids not more than 8 to12 m Eq / L for 24 hours. Patient serum sodium should be monitored for every 4-6hours during the time of iv therapy.

COMPLICATIONS

Complications of CPM include venous thromboembolism, ventilator dependence, muscle wasting, infections such as urinary tract infections, aspiration pneumonia and pressure sores.

SUPPORT THERAPY

 It includes respiratory support, physical therapy and intensive rehabilitation, and antiparkinsonian medications.

PATIENT EDUCATION

Patients must be well educated about the disease condition, therapy options and the clinical outcome of the disease. 10

They have to participate in follow-up at regular intervals after hospital discharge to better assess their clinical clarification.

 

IMPROVE THE RESULTS OF THE HEALTHCARE TEAM

CONCLUSION

REFERENCES

  1. Norenberg MD, Leslie KO, Robertson AS, Association between rise in serum sodium and central pontine myelinolysis, Annals of Neurology Official Journal of the American Neurological Association and the Child Neurology Society, 1982; 11(2):128-35. https://doi.org/10.1002/ana.410110204
  2. Laureno R, Central pontine myelinolysis following rapid correction of hyponatremia, Annals of Neurology, Official Journal of the American Neurological Association and the Child Neurology Society, 1983; 13(3):232-42. https://doi.org/10.1002/ana.410130303
  3. Menger H, Jorg J, Outcome of central pontine and extrapontine myelinolysis (n= 44), Journal of neurology, 1999; 246(8):700-5. https://doi.org/10.1007/s004150050435
  4. Singh T D, Fugate J E, Rabinstein AA, Central pontine and extrapontine myelinolysis a systematic review, European Journal of Neurology, 2014; 21(12):1443-50. DOI: https://doi.org/10.1111/ene.12571
  5. Graff-Radford J, Fugate JE, Kaufmann TJ, Mandrekar JN, Rabinstein AA, Clinical and radiologic correlations of central pontine myelinolysis syndrome, In Mayo Clinic Proceedings 2011; 86(11):1063-1067 DOI: https://doi.org/10.4065/mcp.2011.0239
  6. Alleman AM, Osmotic demyelination syndrome: central pontine myelinolysis and extrapontine myelinolysis. In Seminars in Ultrasound, CT and MRI 2014; 35(2):153-159 DOI: https://doi.org/10.1053/j.sult.2013.09.009  
  7. King JD, Rosner MH, Osmotic demyelination syndrome, Am J Med Sci, 2010 Jun; 339(6):5617. https://doi.org/10.1097/MAJ.0b013e3181d3cd78 .
  8. Renjen PN, Chaudhari D, Namala V, Central pontine and extrapontine myelinolysis, Apollo Medicine, 2016; 13(4):220-223. https://doi.org/10.1016/j.apme.2016.11.001
  9. Sterns RH, Silver S, Kleinschmidt De Masters BK, Rojiani AM, Current perspectives in the management of hyponatremia prevention of CPM, Expert review of neurotherapeutics, 2007; 7(12):1791-7. https://doi.org/10.1586/14737175.7.12.1791
  10. Sterns RH, Hix JK, Silver S. Treating profound hyponatremia a strategy for controlled correction, American journal of kidney diseases, 2010; 56(4):774-9. https://doi.org/10.1053/j.ajkd.2010.04.020
  11. Sterns RH, Hix JK, Overcorrection of hyponatremia is a medical emergency, Kidney international, 2009; 76(6):587-9. DOI: https://doi.org/10.1038/ki.2009.251
  12. Kengne FG, Soupart A, Pochet R, Brion JP, Decaux G, Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats, Kidney international, 2009; 76(6):614-21. DOI: https://doi.org/10.1038/ki.2009.254